Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,564,761
  • Shares Outstanding, K 50,634
  • Annual Sales, $ 13,400 K
  • Annual Income, $ -357,940 K
  • 60-Month Beta 1.47
  • Price/Sales 764.31
  • Price/Cash Flow N/A
  • Price/Book 7.53
Trade MRTX with:

Options Overview

Details
  • Implied Volatility 62.42%
  • Historical Volatility 42.53%
  • IV Percentile 34%
  • IV Rank 19.96%
  • IV High 106.36% on 10/19/20
  • IV Low 51.46% on 11/23/20
  • Put/Call Vol Ratio 35.17
  • Today's Volume 217
  • Volume Avg (30-Day) 221
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 4,257
  • Open Int (30-Day) 2,801

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -2.12
  • Number of Estimates 6
  • High Estimate -1.93
  • Low Estimate -2.36
  • Prior Year -2.02
  • Growth Rate Est. (year over year) -4.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
179.38 +0.90%
on 03/04/21
214.43 -15.59%
on 02/10/21
-19.46 (-9.71%)
since 02/04/21
3-Month
179.38 +0.90%
on 03/04/21
249.42 -27.43%
on 12/14/20
-52.26 (-22.40%)
since 12/04/20
52-Week
66.01 +174.20%
on 03/18/20
249.42 -27.43%
on 12/14/20
+85.12 (+88.78%)
since 03/04/20

Most Recent Stories

More News
Mirati: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Thursday reported a loss of $101.1 million in its fourth quarter.

MRTX : 181.00 (-4.18%)
Mirati: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Thursday reported a loss of $101.1 million in its fourth quarter.

MRTX : 181.00 (-4.18%)
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates

, /PRNewswire/ --  (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the company's progress across...

MRTX : 181.00 (-4.18%)
Global Advanced Urotheilal carcinoma Pipeline Insight Report 2021 Featuring Rogaratininb (Bayer) & Sitravatinib (Mirati Therapeutics) - ResearchAndMarkets.com

The "Advanced Urotheilal carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

MRTX : 181.00 (-4.18%)
Global AXL Kinase inhibitor Pipeline Insights 2021: Emerging Drugs Include Sitravatinib (Mirati Therapeutics) and Bemcentinib (BerGenBio / Rigel Pharmaceuticals) - ResearchAndMarkets.com

The "AXL Kinase inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

MRTX : 181.00 (-4.18%)
RIGL : 3.58 (-6.53%)
Mirati Therapeutics To Present At Upcoming Healthcare Conferences

, /PRNewswire/ -- . (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.

MRTX : 181.00 (-4.18%)
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors

and , /PRNewswire/ --  and  (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational...

MRTX : 181.00 (-4.18%)
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim Healthcare Talks 2021...

MRTX : 181.00 (-4.18%)
Resolution Bioscience Announces Companion Diagnostic Collaboration with Mirati Therapeutics

Resolution Bioscience, Inc. today announced a companion diagnostic agreement with Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company. As part of the agreement, Resolution's...

MRTX : 181.00 (-4.18%)
Worldwide Indsutry for KRAS Inhibitors to 2025 - Players Include Amgen, Mirati Therapeutics & Revolution Medicines Among Others

The "Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025" report has been added to ResearchAndMarkets.com's offering.

AMGN : 221.91 (-0.91%)
MRTX : 181.00 (-4.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.

See More

Key Turning Points

3rd Resistance Point 196.51
2nd Resistance Point 192.76
1st Resistance Point 186.88
Last Price 181.00
1st Support Level 177.25
2nd Support Level 173.50
3rd Support Level 167.62

See More

52-Week High 249.42
Last Price 181.00
Fibonacci 61.8% 179.36
Fibonacci 50% 157.71
Fibonacci 38.2% 136.07
52-Week Low 66.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar